Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is a leading innovator in the field of surgical treatments for cardiovascular diseases, specifically atrial fibrillation and left atrial appendage management. The company's diverse product line and strong sales force make it well-positioned for continued growth in the coming years. The recent 4Q25 results and 2026 guidance showcase the company's potential for double-digit growth and improved profitability. AtriCure also has additional potential opportunities in pain management and minimally invasive procedures, which could further drive revenue and margin expansion. With a low EV/revenue multiple and multiple potential growth drivers, AtriCure has a positive outlook for durable revenue growth and improved profitability.

Bears say

AtriCure is facing multiple challenges, including declining sales in its minimally invasive ablation platform and reimbursement pressure in its fastest growing European market, which are expected to continue in 2026. While the company has promising clinical trials and potential for improved sales and margins, these factors are currently overshadowed by the challenges and do not provide enough confidence for a positive outlook.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.